GLP-1 'slander' vs. real side effect data: what's fair criticism?

What's this video probably claiming?

Based on the caption and category, @lararoseb is almost certainly pushing back against negative coverage of GLP-1 receptor agonists, specifically semaglutide and related drugs. The "slander needs to stop" framing is a recurring TikTok genre where creators defend these medications against what they frame as fearmongering, usually touching on a few predictable arguments: that side effects are exaggerated, that weight regain after stopping is unfair to blame on the drug, that the "Ozempic face" panic is overblown, or that critics are just perpetuating fatphobia in a medical disguise. Some versions of this content are genuinely useful corrections to bad-faith media coverage. Others overcorrect and end up dismissing legitimate safety signals. Without the transcript, we're working in the space between those two possibilities, which is exactly where this kind of content tends to live.

What does the science actually show?

The efficacy data for semaglutide is real and not trivial. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed that 2.4 mg subcutaneous semaglutide weekly produced roughly 14.9% mean body weight loss over 68 weeks versus 2.4% in placebo, with about one-third of participants losing 20% or more. Tirzepatide data from SURMOUNT-1 (Jastreboff et al., 2022, NEJM) pushed those numbers further, with up to 22.5% mean weight loss at the highest dose. These are genuinely significant outcomes that earlier anti-obesity pharmacology never came close to. But the same studies document gastrointestinal adverse events in 70-80% of participants at therapeutic doses, with nausea reported in roughly 44% and vomiting in 24%. These aren't rare edge cases. They are expected pharmacological effects of slowing gastric emptying.

Where does the social media noise diverge from clinical reality?

The biggest distortion in pro-GLP-1 content is the framing of side effects as purely a misinformation problem. Some side effect coverage is sensationalized. "Ozempic face" as a discrete medical phenomenon is not well-defined in peer-reviewed literature and largely reflects rapid fat redistribution from fast weight loss rather than a drug-specific effect. Fair point. But the dismissal of gastroparesis risk as internet hysteria is harder to defend. A 2023 study by Sodhi et al. in JAMA found GLP-1 receptor agonists were associated with a 9.09 times higher incidence of gastroparesis compared to bupropion-naltrexone in a matched cohort using GLP-1s for weight loss specifically, not diabetes. Pancreatitis signals, while debated, have not been fully resolved. The rebound weight gain data is also not slander. The STEP 1 extension (Wilding et al., 2022, Obesity) showed participants regained roughly two-thirds of lost weight within one year of stopping. That's not a smear campaign. That's the drug doing what it does.

What should you actually know?

GLP-1 receptor agonists are among the most effective weight management tools in the current pharmacological toolkit. Dismissing all criticism as slander is as epistemically lazy as dismissing all benefits as pharma hype. Patients deserve a calibrated picture. The drugs work, meaningfully, for a significant subset of people with obesity-related metabolic risk. The side effect burden is real and not trivial, particularly GI effects and the under-discussed psychological dimension: some users report changes in appetite signaling that affect their relationship with food in ways that warrant monitoring. Discontinuation planning matters because these drugs are, for most people, long-term commitments rather than courses of treatment. A clinician-supervised approach, with clear expectations set before starting, is not optional context. It is the difference between a good outcome and a frustrating one. TikTok content defending these drugs performs a service when it corrects genuine misinformation. It does a disservice when it shuts down legitimate clinical nuance.